Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
47 Cards in this Set
- Front
- Back
MOA of cimetidine
|
Reversible H2 blocker. Decreases H+ secretion by parietal cells
|
|
MOA of ranitidine
|
Reversible H2 blocker. Decreases H+ secretion by parietal cells
|
|
MOA of famotidine
|
Reversible H2 blocker. Decreases H+ secretion by parietal cells
|
|
MOA of nizatidine
|
Reversible H2 blocker. Decreases H+ secretion by parietal cells
|
|
Clinical uses of H2 blockers
|
Peptic ulcer, gastritis, mild esophageal reflux
|
|
Side effects of cimetidine
|
CYP450 inhibitor, antiandrogenic (prolactin release, gynecomastia, impotence, decreased libido in males), CNS effects (can cross BBB and cause confusion, dizziness, headaches) and can cross placenta
|
|
These two H2 blockers decrease renal excretion of creatinine
|
Cimetidine, ranitidine
|
|
MOA of omeprazole
|
Irreversible inhibitor of H/K-ATPase in parietal cells (proton pump inhibitor)
|
|
MOA of lansoprazole
|
Irreversible inhibitor of H/K-ATPase in parietal cells (proton pump inhibitor)
|
|
Treatment for Zollinger-Ellison syndrome
|
Proton pump inhibitors (omeprazole, lansoprazole)
|
|
Clinical uses of PPI's
|
Peptic ulcer, gastritis, esophageal reflux, Zollinger-Ellison syndrome
|
|
MOA of bismuth
|
Binds to base of ulcers, providing physical protection, and permits HCO3- secretion to reestablish pH gradient in mucosal layer
|
|
MOA of sucralfate
|
Same as bismuth (protects mucosa, facilitates HCO3- secretion)
|
|
Triple therapy of H. pylori ulcers
|
Metronidazole, amoxicillin (or tetracycline), bismuth; can also use a PPI
("P.lease M.A.ke T.ummy B.etter") |
|
MOA of misoprostol
|
PGE1 analog. Increases mucus, decreases acid in stomach
|
|
Clinical use of misoprostol
|
Prevention of NSAID-induced peptic ulcers, maintains patent ductus arteriosus, induces labor
|
|
This GI drug is contraindicated in women of childbearing potential
|
Misoprostol
|
|
These muscarinic antagonists are used to treat peptic ulcers (rarely)
|
Pirenzepine, propantheline
|
|
MOA of pirenzepine
|
MI receptor blocker on ECL cells (lowers histamine secretion). M3 receptor blocker on parietal cells (lowers H+ secretion).
|
|
MOA of propantheline
|
M1 receptor blocker on ECL cells (lowers histamine secretion). M3 receptor blocker on parietal cells (lowers H+ secretion).
|
|
These drugs cause tachycardia, dry mouth and difficulty focusing eyes
|
Muscarinic antagonists
|
|
These are the antacids (3)
|
Aluminum hydroxide, magnesium hydroxide, calcium carbonate
|
|
All antacids have this as their possible side effect
|
Hypokalemia
|
|
These drugs can affect absorption, bioavailability, or urinary excretion of other drugs
|
Antacids. They delay gastric emptying, and alter gastric pH and urinary pH
|
|
Side effects of aluminum hydroxide
|
Constipation, hypophosphatemia; proximal muscle weakness, osteodystrophy, seizures
("aluMinimum amount of feces") |
|
Side effects of magnesium hydroxide
|
Diarrhea, hyporeflexia, hypotension, cardiac arrest
("Mg=Must go [to the bathroom]") |
|
Side effects of calcium carbonate
|
Hypercalcemia, rebound acid increase, chelates other drugs and reduces their effectiveness (eg, tetracyclines)
|
|
This drug can chelate tetracycline and reduce its effectiveness
|
Calcium carbonate
|
|
MOA of infliximab
|
Antibody to TNF (TNF is a pro-inflammatory cytokine)
|
|
Indications for infliximab
|
Crohn's disease, rheumatoid arthritis, ankylosing spondylitis
|
|
Side effects of infliximab
|
Respiratory infection (including reactivation of latent TB), fever, hypotension
|
|
This drug can cause reactivation of latent TB
|
Infliximab
|
|
This drug is activated by colonic bacteria
|
Sulfasalazine
|
|
MOA of sulfasalazine
|
Combination of sulfapyridine (antibacterial) and mesalamine (anti-inflammatory)
|
|
This drug is a combination of sulfapyridine and mesalamine
|
Sulfasalazine
|
|
Indications for sulfasalazine
|
IBD (ulcerative colitis, Crohn's disease)
|
|
This drug can cause reversible oligospermia
|
Sulfasalazine
|
|
MOA of ondansetron
|
5-HT3 blocker
|
|
This drug is a powerful central-acting antiemetic
|
Ondansetron
|
|
This drug is given to control vomiting postoperatively and in chemotherapy
|
Ondansetron
|
|
Side effects of ondansetron
|
Constipation, headache
|
|
MOA of metoclopramide
|
D2 receptor blocker
|
|
This drug increases resting tone, contractility, lower esophageal sphincter tone, and motility; but does not influence colon transport time
|
Metoclopramide
|
|
Indications for metoclopramide
|
Gastroparesis (as in diabetics, post-surgical patients)
|
|
Side effects of metoclopramide
|
Parkinsonian effects
|
|
This drug is contraindicated in patients with small bowel obstruction
|
Metoclopramide
|
|
This drug interacts with digoxin and diabetic agents
|
Metoclopramide
|